Olema Pharmaceuticals (OLMA) Stock Jumps on Rival’s Positive Cancer Trial Results

TLDR

• Olema Pharmaceuticals stock jumped 197.3% in pre-market trading Tuesday despite no company announcements
• Swiss drugmaker Roche reported positive Phase III trial results for giredestrant, a breast cancer treatment
• Olema is developing palazestrant, a similar drug for breast cancer treatment in partnership with Novartis
• Roche’s study met its primary endpoint in an interim analysis for early-stage breast cancer patients
• Pre-market volume reached 13.4 million shares versus a three-month average of 1.28 million shares

---

Olema Pharmaceuticals stock surged Tuesday morning without any direct news from the company. The clinical-stage biopharmaceutical company issued no press releases or SEC filings to explain the movement.

Olema Pharmaceuticals, Inc., OLMA

The catalyst came from competitor Roche instead. The Swiss drugmaker announced positive Phase III clinical trial results for its investigational drug giredestrant.

Roche’s study focused on using giredestrant as an adjuvant endocrine treatment. The trial included patients with estrogen receptor-positive, HER2-negative, early-stage breast cancer.

The study met its primary endpoint during an interim analysis. However, overall survival data remains unavailable at this time.

Connection to Olema’s Drug Development

The news matters to Olema because of palazestrant, the company’s lead asset. This drug shares similarities with Roche’s giredestrant. Both target breast cancer treatment.

Olema currently runs several clinical trials for palazestrant. The company works under an agreement with Novartis on these studies.

Roche’s positive trial results suggest potential validation for this class of drugs. Investors interpreted the news as favorable for Olema’s similar compound.

Stock Performance and Trading Activity

Olema Pharmaceuticals stock climbed 197.3% in pre-market trading Tuesday. The previous trading session saw a 1.43% gain.

Year-to-date performance shows a 46.14% increase for the stock. Over the past 12 months, shares have risen 2.29%.

Trading volume spiked dramatically Tuesday morning. Pre-market activity reached 13.4 million shares.

This represents a massive increase from normal levels. The three-month daily average sits at approximately 1.28 million shares.

Analyst Outlook

Wall Street maintains a Strong Buy consensus rating on Olema Pharmaceuticals. Six analysts issued Buy ratings over the past three months.

The average price target stands at $24.25 per share. This represents a potential upside of 184.62% from current levels.

No analysts have issued Sell or Hold ratings during this period. The unanimous positive stance reflects confidence in the company’s pipeline.

Roche’s giredestrant trial included patients with estrogen receptor-positive, HER2-negative, early-stage breast cancer. Pre-market trading volume for Olema reached 13.4 million shares on Tuesday, compared to a three-month daily average of about 1.28 million units.

The post Olema Pharmaceuticals (OLMA) Stock Jumps on Rival’s Positive Cancer Trial Results appeared first on Blockonomi.